Introduction
============

An association between rheumatoid arthritis (RA) and increased cardiovascular disease burden has been recognised for many years \[[@B1]\]. This results in excess mortality and reduced lifespan compared with the general population \[[@B2],[@B3]\]. Many factors may contribute to the increased cardiovascular risk, including classical risk factors such as smoking, diabetes, hypertension, and obesity and novel risk factors such as systemic inflammation, a prothrombotic state, and hyperhomocystinaemia \[[@B4]\].

Glucocorticoids (GCs) are known to have beneficial effects in controlling rheumatoid inflammation \[[@B5],[@B6]\] but their use has been curbed due to their adverse effects. They are used increasingly as a short-term measure to induce rapid reduction in disease activity whilst awaiting the effects of slower acting disease-modifying anti-rheumatic drugs (DMARDs) \[[@B7]\]. Long-term use of GCs is controversial due to an undesirable side effect profile that includes dyslipidaemia \[[@B8]\], hyperglycaemia \[[@B9]\], insulin resistance \[[@B10]\], hypertension \[[@B11],[@B12]\], and central obesity \[[@B11]\]: these may collectively contribute to the development of the metabolic syndrome \[[@B13],[@B14]\] and atherosclerosis \[[@B15],[@B16]\].

The metabolic syndrome, first described by Reaven in 1988 \[[@B17]\], is a cluster of classical cardiovascular risk factors (obesity, glucose intolerance, dyslipidaemia, and hypertension) thought to associate with cardiovascular risk beyond the sum of its individual components \[[@B18]\], although this has recently been questioned \[[@B19]\]. It is estimated that the metabolic syndrome affects 20% to 30% of the adult population in developed countries \[[@B20]-[@B22]\] but its prevalence varies according to the definition used as well as environmental and genetic differences between populations \[[@B22]\]. As a consequence of physical inactivity and poor diet, rates of obesity and diabetes are increasing worldwide \[[@B23],[@B24]\], with an expected exponential rise in the percentage of the population affected by the metabolic syndrome \[[@B23]\]. The pathogenesis underlying the clustering of cardiovascular risk factors remains unclear: genetic predisposition, obesity, and inflammation have been suggested to be involved \[[@B25],[@B26]\]. A recent study has shown that patients with RA have a higher prevalence of metabolic syndrome than controls \[[@B27]\], although another study has demonstrated an equally high prevalence between Mediterranean RA patients and local general population controls \[[@B28]\]. In the present cross-sectional study, we addressed the hypothesis that RA patients receiving long-term GC will have an increased prevalence of each of the individual components of the metabolic syndrome (dyslipidaemia, hypertension, hyperglycaemia, and central obesity) as well as the metabolic syndrome itself.

Materials and methods
=====================

RA patients (n = 398) fulfilling the revised American College of Rheumatology criteria \[[@B29]\] were recruited from routine outpatient clinics at the Department of Rheumatology, Dudley Group of Hospitals NHS Trust (Dudley, West Midlands, UK). Characteristics of the study population are shown in Table [1](#T1){ref-type="table"}. Local ethics committee approval was granted for the study and all participants provided informed consent.

###### 

Demographics and clinical and laboratory characteristics of the glucocorticoid exposure groups

                                                    NE (n = 281)        LE (n = 58)          ME (n = 59)         *P*value
  ------------------------------------------------- ------------------- -------------------- ------------------- ----------
  General demographics                                                                                           
   Age, years                                       62 (53.03--68.56)   66.01 (59--71.47)    66.6 (60.7--71.6)   0.002
   Gender female, number (percentage)               214 (76.2)          41 (70.7)            36 (61)             0.053
  RA characteristics                                                                                             
   RF-positive, number (percentage)                 210 (76.4)          42 (73.7)            43 (75.4)           0.909
   Anti-CCP-positive, number (percentage)           181 (67.5)          36 (63.2)            41 (73.2)           0.517
   Disease duration, years                          7 (3--15)           16 (10--25.5)        18 (10--39)         \<0.001
  Disease activity                                                                                               
   CRP, mg/L                                        8 (5--18)           8 (5--17)            9 (5--28)           0.421
   ESR, mm/h                                        20 (10--38)         15.5 (6.75--29.25)   26 (12--45)         0.031
   DAS-28                                           4.15 ± 1.38         4.09 ± 1.37          4.59 ± 1.47         0.080
  Disease severity                                                                                               
   HAQ                                              1.38 (0.5--2)       1.63 (0.72--2.16)    2.13 (1.63--2.5)    \<0.001
   Extra-articular disease, number (percentage)     180 (64.1)          42 (72.4)            45 (76.3)           0.124
   Joint replacement surgery, number (percentage)   65 (23.1)           21 (36.2)            29 (49.2)           \<0.001
  Medications                                                                                                    
   Methotrexate, number (percentage)                161 (57.3)          35 (60.3)            28 (47.5)           0.305
   Sulphasalazine, number (percentage)              96 (34.2)           11 (19)              11 (18.6)           0.009
   Hydroxychloroquine, number (percentage)          57 (20.3)           13 (22.4)            10 (16.9)           0.754
   Leflunomide, number (percentage)                 11 (3.9)            1 (1.7)              4 (6.8)             0.374
   Anti-TNF, number (percentage)                    29 (10.3)           9 (15.5)             7 (11.9)            0.518
   NSAIDS/COX II, number (percentage)               82 (29.2)           15 (25.9)            13 (22)             0.508
  Risk factors for the MetS                                                                                      
   Waist, cm                                        97.12 ± 12.39       97.35 ± 14.3         100.9 ± 15.19       0.172
   Trigylcerides, mmol/L                            1.2 (0.9--1.6)      1.2 (0.9--1.63)      1.4 (1.1--1.8)      0.010
   Systolic blood pressure, mm Hg                   140 (126.25--150)   142 (125.75--159)    145 (135--160)      0.022
   Diastolic blood pressure, mm Hg                  78.66 ± 10.85       79.97 ± 10.82        79.06 ± 13.06       0.716
   HDL, mmol/L                                      1.5 (1.2--1.8)      1.7 (1.38--2.03)     1.7 (1.4--2)        0.011
   LDL, mmol/L                                      5.2 ± 1.07          5.31 ± 1.27          5.25 ± 1.54         0.798
  Criteria for MetS                                                                                              
   Waist M, number (percentage)                     163 (65.2)          32 (65.3)            36 (69.2)           0.853
   Triglycerides M, number (percentage)             96 (34.2)           24 (41.4)            31 (52.5)           0.026
   Hypertension M, number (percentage)              220 (78.3)          45 (77.6)            55 (93.2)           0.027
   HDL M, number (percentage)                       94 (33.5)           20 (34.5)            24 (40.7)           0.570
   Fasting plasma glucose M, number (percentage)    38 (13.5)           9 (15.8)             14 (24.1)           0.125
  Patients fulfilling criteria of MetS                                                                           
   NCEP, number (percentage)                        105 (37.9)          22 (40.7)            28 (50.0)           0.241

Results expressed as number (percentage), median (25th--75th percentile), or mean ± standard deviation, as appropriate. Anti-CCP, anti-cyclic citrullinated peptide; anti-TNF, anti-tumour necrosis factor therapy; CRP, C-reactive protein; HAQ, health assessment questionnaire; DAS-28, 28-joint disease activity score; ESR, erythrocyte sedimentation rate; Triglycerides M, triglycerides of at least 1.7 mmol/L or on drug treatment for elevated triglycerides; Waist M, waist circumference of greater than 102 cm in males and greater than 88 cm in females. Fasting plasma glucose M, fasting plasma glucose of at least 6.1 mmol/L or on drug treatment for elevated blood glucose; HDL, high-density lipoprotein; HDL M, high-density lipoprotein level of less than 1.0 mmol/L in males or less than 1.3 mmol/L in females or on drug treatment for low HDL; Hypertension M, systolic blood pressure of at least 130/85 mm Hg or on antihypertensive medication; LDL, low-density lipoprotein; LE, low-dose/long-term exposure; ME, moderate-dose/long-term exposure; MetS, metabolic syndrome; NCEP, National Cholesterol Education Programme; NE, none/limited exposure; NSAIDs/COX II, nonsteroidal anti-inflammatory drugs/cyclooxygenase II inhibitors; RA, rheumatoid arthritis; RF, rheumatoid factor;

All patients underwent the same baseline evaluation prospectively. The following details were recorded: basic demographics (that is, age, gender, height, weight, and waist circumference), a full medical history (including specific details regarding RA and cardiovascular disease), and current disease activity and physical function, using the 28-joint disease activity score (DAS-28) \[[@B30]\] and health assessment questionnaire (HAQ) \[[@B31]\], respectively. All current medications, including anti-rheumatic drugs, analgesics, and cardiovascular drugs such as statins or anti-hypertensives, were documented. Information regarding GC (oral prednisolone) dose and duration of exposure was recorded and categorised into none or low-dose (\<7.5 mg of prednisolone daily), limited duration (\<3 months) GC exposure (no exposure, NE), low-dose long-term (\>6 months) (low exposure, LE), or medium-dose (prednisolone at least 7.5 to 30 mg daily for more than 6 months) long-term (medium exposure). There were no patients exposed to high-dose long-term GC. Baseline blood samples, including fasting lipid profiles (total cholesterol, triglycerides (TGs), and high-density lipoproteins (HDLs)), erythrocyte sedimentation rate (ESR), C-reactive protein, fasting glucose, insulin, and rheumatoid factor, were taken. All blood tests were analysed by a single laboratory. The metabolic syndrome was classified by National Cholesterol Education Programme III (NCEP III) criteria \[[@B32]\]: fasting plasma glucose of at least 6.1 mmol/L or on drug treatment for elevated blood glucose, systolic blood pressure of at least 130/85 mm Hg or on drug treatment for elevated blood pressure, TG at least 1.7 mmol/L or drug treatment for elevated TG, HDL in males of less than 1.0 mmol/L and in females of less than 1.3 mmol/L or on drug treatment for a low HDL, and waist circumferences in males of greater than 102 cm and in females of greater than 88 cm, with the metabolic syndrome defined as the presence of at least three of these criteria \[[@B32]\].

Analysis of the data was carried out using SPSS 14.0 (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was used to evaluate the distribution of each parameter. Values were expressed as mean ± standard deviation, median (25th--75th percentile), or number (percentage), as appropriate. Comparisons were performed by analysis of variance, Kruskal-Wallis, and chi-square test for normally distributed, non-normally distributed, and categorical variables, respectively. To evaluate the independence of the association between GC exposure and the metabolic syndrome, binary logistic regression analysis was used.

Results
=======

Descriptive characteristics of the population studied
-----------------------------------------------------

Median (interquartile range) age in the total cohort was 63.08 (55.46 to 69.62) years, disease duration was 10 (4 to 18) years, and 292 (73%) of the patients were female. Three hundred forty patients (87.4%) were receiving DMARDs (two thirds as monotherapy and the remaining as combination therapy), of whom 225 (56.3%) were taking methotrexate, 118 (29.5%) sulphasalazine, 80 (20%) hydroxycholoroquine, 16 (4%) leflunomide, and 46 (11.5%) anti-tumour necrosis factor (anti-TNF) biologics; 111 patients (27.8%) were on nonsteroidal anti-inflammatory drugs or cyclooxygenase II inhibitors. One third of the cohort, 117 patients (29.4%), were taking GCs, with similar numbers in the LE and ME groups (58 versus 59 patients, respectively). Other drugs included statins in 83 (20.8%) and antihypertensives in 177 (44.5%) patients. Further baseline characteristics of the study population are described in detail in previous papers by our group \[[@B12],[@B33]\].

Univariate analysis
-------------------

Patients in the LE and ME groups were older (*P*= 0.002) and had longer disease duration (*P*\< 0.001) and higher ESR (*P*= 0.031) and HAQ (*P*\< 0.001) and more frequent joint replacement surgery (*P*\< 0.001) than those in the NE group (Table [1](#T1){ref-type="table"}). There were no significant differences between LE and ME. Of the risk factors for the metabolic syndrome, TG, systolic blood pressure, and HDL were all higher in patients receiving long-term GCs (LE or ME). TGs were significantly higher in the ME group (*P*= 0.010) compared with NE, but no significant difference was noted between LE and NE. Systolic blood pressure increased as GC exposure increased (NE 140 (126.25 to 150) mm Hg versus LE 142 (125.75 to 159) mm Hg versus ME 145 (135 to 160) mm Hg, *P*= 0.022). Interestingly, HDL levels were higher in the LE and ME groups (*P*= 0.011).

The individual components that comprise the metabolic syndrome were analysed to assess the proportion of patients in each of the GC exposure groups fulfilling the NCEP III-defined cut off levels. TG levels adequate for contributing as a component of the metabolic syndrome were observed in a significantly higher proportion of patients in the LE and ME groups compared with NE (*P*= 0.026). The NCEP III cut off for hypertension was present in a significantly higher proportion of patients in the ME group (*P*= 0.027) but not in the LE group. The other individual components that contribute to the definition of the metabolic syndrome (waist circumference, HDL, and fasting plasma glucose) were observed in similar proportions of patients within the NE, LE, and ME groups.

On combining the individual components to fulfil the NCEP III criteria for the metabolic syndrome (presence of at least three of the components), there was no evidence of a significant association between the degree of GC exposure and the presence of the metabolic syndrome (NE 105 (37.9%) versus LE 22 (40.7%) versus ME 28 (50%), *P*= 0.241). Factors identified to be significantly associated with both the metabolic syndrome and GC exposure, thus acting as potential confounders, included age (*P*= 0.001 and *P*= 0.002, respectively), RA disease duration (*P*= 0.008 and *P*\< 0.001), ESR (*P*= 0.006 and *P*= 0.031), and HAQ (*P*= 0.036 and *P*\< 0.001).

Multivariate analysis
---------------------

The association between GC exposure and the frequency of the metabolic syndrome was assessed using a logistic regression model (Table [2](#T2){ref-type="table"}). The analysis did not demonstrate a statistically significant association between LE (odds ratio (OR) = 1.13 (0.62 to 2.04), *P*= 0.695) or ME (OR = 1.64 (0.92 to 2.92), *P*= 0.094) and the metabolic syndrome in either the crude model or following adjustment for all of the potential confounders mentioned above (age, ESR, disease duration, and HAQ; for completeness, gender was also added to the model): LE OR = 1.15 (0.61 to 2.19) (*P*= 0.670) and ME OR = 1.4 (0.72 to 2.58) (*P*= 0.340). For reasons of colinearity, ESR and DAS could not be included in the same model. However, to ensure that disease activity *per se*(rather than ESR alone) did not alter the results, the model was repeated including DAS instead of ESR. Despite this, no significant association was found between LE (OR = 1.189, *P*= 0.601) or ME (OR = 1.453, *P*= 0.262) and the metabolic syndrome.

###### 

Odds ratios for the metabolic syndrome (NCEP III) in comparison with the amount of steroid exposure

            LD/LTE               MD/LTE                       
  --------- -------------------- -------- ------------------- -------
  Crude     1.13 (0.62--2.04)    0.695    1.64 (0.92--2.92)   0.094
  Model a   0.998 (0.54--1.83)   0.994    1.37 (0.75--2.48)   0.304
  Model b   1.15 (0.61--2.19)    0.670    1.4 (0.72--2.58)    0.340

Crude = uncorrected data. Model a = crude data plus adjustment for age and gender. Model b = model a plus adjustment for markers of disease activity/severity (disease duration, erythrocyte sedimentation rate levels, and health assessment questionnaire). CI, confidence interval; LD/LTE, low-dose/long-term exposure; MD/LTE, moderate-dose/long-term exposure; NCEP III, National Cholesterol Education Programme III; OR, odds ratio.

Discussion
==========

This cross-sectional observational study has demonstrated that long-term exposure to GCs, particularly at medium doses, is associated with increased prevalence of two of the components of the metabolic syndrome (high TG and hypertension), but not any of the other components (low HDL, obesity, and glucose intolerance) or the presence of the metabolic syndrome itself. We have presented data having used the NECP III criteria for metabolic syndrome as they are the most up-to-date and widely used, allowing comparison of our results with those of other studies in RA and other conditions. However, for the purpose of completeness, we have also analysed the data on the basis of other metabolic syndrome classification criteria, including those of the World Health Organisation \[[@B34]\], the International Diabetes Federation \[[@B35]\], and the European Group for the Study of Insulin Resistance \[[@B36]\], in order to ensure that the definition used would not affect the outcome of this study. The lack of any association between GC exposure and the presence of the metabolic syndrome in this RA cohort was present irrespective of the metabolic syndrome criteria used (data not shown).

Although no statistically significant association between GC exposure and the metabolic syndrome was found, the multivariate analysis did demonstrate a trend in the OR as steroid exposure increased (LE 1.13 (0.62 to 2.04) versus ME 1.64 (0.92 to 2.92)). Thus, a possible limitation of the present study may be that, despite the fact that it is by far the largest to date to assess metabolic syndrome in RA, its power may not have been sufficient to detect such an association, although the clinical significance of such a weak association would then come into question. The most important limitation of this study, however, is its cross-sectional design, which does not allow definitive interpretation of the causality and directionality of the associations found. Notwithstanding these limitations, this study has addressed an original question that has not been addressed elsewhere in the literature in a large, very well-characterised RA population, with prospective data collection, thus allowing adjustment for many potential confounders and minimising selection and recall bias or missing values, which are all common problems in retrospective studies.

The absence of a relationship between long-term GC use and the presence of the metabolic syndrome may be explained by physical and metabolic changes occurring as part of the disease process or as an indirect consequence of treatments other than steroids \[[@B37]-[@B39]\]. It is possible that the beneficial effects produced by suppressing the impact of inflammation on the metabolic syndrome may outweigh the harmful effects of GCs. For example, in RA, many components of the lipid profile are suppressed by the ongoing inflammatory burden, including HDL \[[@B40]\]. However, suppression of the inflammatory load via drug use (for example, DMARDs) produces a significant increase in lipid levels, particularly HDL \[[@B41]\]. Conversely, it may be that patients with RA have significantly modified their risk factors for the metabolic syndrome as a consequence of inflammation and that the addition of GC use cannot worsen these further.

Central obesity is associated with increased cardiovascular risk and is one of the components of the metabolic syndrome. GC use has been shown to redistribute body fat and result in central obesity with relative sparing of the extremities \[[@B42]\]. Long-term GC use can also be complicated by the development of a steroid-induced myopathy \[[@B37]-[@B39],[@B43]\], which may further exacerbate the imbalance between fat mass and muscle bulk. Although steroid myopathy primarily manifests with proximal muscle weakness in the absence of muscle atrophy \[[@B44]\], muscle wasting may occur as a consequence of a reduction in functional capacity. The systemic inflammation associated with RA causes a hypercatabolic state, which, together with a sedentary lifestyle, results in a loss of muscle bulk and an increased tendency to gain fat in the presence of stable or even slightly decreased weight, often referred to as rheumatoid cachexia \[[@B45]\]. It has been reported that almost two thirds of patients with RA have features of rheumatoid cachexia \[[@B46]\], and a recent study has demonstrated the need for redefining the body mass index in RA to take into account these changes \[[@B33]\]. It is therefore possible that, in RA patients, alterations in body fat/muscle may have already occurred as part of the disease process and thus any additional changes that are induced by long-term GC exposure may be insignificant. Alternatively, better control of inflammation due to steroid usage may counterbalance some of the body composition abnormalities that would have otherwise occurred. The latter possibility would be supported by our findings in RA patients treated with anti-TNF biologics \[[@B47]\].

A relationship between RA and abnormalities in the lipid profile has been observed for several decades \[[@B48]\], with the key contributing factor thought to be inflammation \[[@B49]\]. The typical pattern of dyslipidaemia seen in active RA is a reduction in total cholesterol, low-density lipoprotein, and HDL \[[@B40]\]. Data regarding TG levels in RA are conflicting, with some studies reporting an increase \[[@B50]\] and others a decrease \[[@B51]\]. The metabolic syndrome definition takes in to account only two components of the lipid profile, TG and HDL. GC use, independent of dose, has been shown to increase HDL levels \[[@B52]-[@B54]\]. Endogenous GC hormones regulate HDL plasma concentrations by increasing synthesis and secretion by the liver \[[@B55]\]. Consequently, high doses of exogenous GCs such as those being received by RA patients are likely to accelerate this pathway. Therefore, in RA, HDL levels previously suppressed by disease activity will rise, producing a less atherogenic profile. This was reflected in our study, in which an increase in HDL levels was seen in patients receiving long-term GCs (*P*= 0.011). The observed rise in HDL levels may also be explained by the indirect effects of GCs. Patients requiring GCs as part of their disease management are likely to have aggressive disease, which contributes to a reduction in mobility as a result of joint stiffness and damage. Therefore, GC use in this subset of patients may result in suppression of disease activity and allow patients to lead a more active lifestyle with a further beneficial effect on HDL levels \[[@B56]\].

Elevation of TG levels in patients receiving GCs on a long-term basis has also been demonstrated \[[@B57],[@B58]\]. However, many of the studies have been limited due to the lack of control for other potential lipid-influencing factors such as metabolic, nutritional, or comorbid conditions. Although the proportion of patients fulfilling the NCEP III-specified cut off levels for TGs was significantly higher in the group receiving long-term GCs in this study (*P*= 0.026), this alone was not sufficient to impact significantly on the overall prevalence of the metabolic syndrome, possibly being counterbalanced by increases in HDL, producing an overall less atherogenic lipid profile.

Shortly after the discovery of GC by Hench and colleagues \[[@B59]\] in 1948, it became apparent that patients were frequently developing adverse effects, including hypertension and diabetes \[[@B60]\]. Despite this, there is limited evidence to support these initial observations. In the general population, studies attempting to assess the association between GC use and hypertension have been hampered by poor study design \[[@B61]\], thus resulting in a distinct lack of direct evidence to support this relationship. In RA, this association has been studied in more detail, with two recent studies demonstrating an increase in blood pressure in patients treated with long-term medium-dose (≥ 7.5 mg) GC \[[@B12],[@B62]\]. One of these studies, a large cross-sectional study, confirmed an association independent of other risk factors for hypertension and RA disease activity or severity \[[@B12]\]. Although it appears that there is a link between GC exposure and hypertension in RA, it has also been speculated that RA itself may predispose patients to an increased prevalence of hypertension \[[@B63]\]. The data produced in the present study show a significant increase in the numbers of patients fulfilling the NCEP III-specified cut off levels for hypertension (= 130/85 mm Hg or taking anti-hypertensives) in those receiving long-term GC. It may be that, despite hypertension being prevalent in RA, there is still scope for further modification through the actions of GCs. Irrespective of this, it appears again that the increased frequency of patients satisfying both the hypertensive and hypertrigylceridaemic components of the metabolic syndrome in the steroid-treated group is not sufficient to also increase the frequency of those qualifying for a diagnosis of the metabolic syndrome.

GC-induced hyperglycaemia is a well-recognised complication of long-term GC use \[[@B64]\]. It is known that patients with active RA have impaired glucose handling and that glucose metabolism may be affected directly or indirectly by inflammatory mediators \[[@B65]\]. Several studies have demonstrated an association between GC use and decreased insulin sensitivity \[[@B10],[@B66],[@B67]\]. However, there is smaller bank of conflicting data demonstrating that GC use in RA paradoxically restores glucose handling to normal whilst also inducing hyperinsulinism \[[@B68]\]. In the present RA population, it is possible that GC use restored glucose handling to normal via anti-inflammatory mechanisms, hence explaining why this component was not significant in the univariate analysis and had no impact on the frequency of the metabolic syndrome.

Conclusion
==========

In summary, this study suggests that the presence of the metabolic syndrome in RA appears to be independent of the use of GCs. It is possible that the disease process itself is the key contributor. This would suggest that effective management of metabolic syndrome in RA is likely to require a two-pronged approach: identification and management of individual classical risk factors, particularly hypertension and hypertriglyceridaemia, as well as aggressive control of inflammatory disease activity with available means, including judicious usage of GCs.
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